Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Lucid Colloids Ltd

    Lucid Colloids Limited (LCL), established in July 1996 by Mr Uday Merchant, is engaged in manufacturing and sale of Guar gum and its derivatives. LCL had its beginnings in 1958

  • No Image
    Lumis Biotech Pvt Ltd

    Lumis Biotech Pvt Ltd was incorporated in the year 1994 is engaged in the manufacturing of enzymes, ie, phytase, xylanase, amylase, protease, cellulose, lipase and others which

  • No Image
    Lupin Ltd

    Lupin Ltd company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish t

  • No Image
    Lyka Labs Ltd

    Lyka undertakes Manufacturing Activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire Manufacturing proce